Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective

Niklas Gebauer; Harald Biersack; Ann Cathrin Czerwinska; Janina Schemme; Tim Tristan Hardel; Veronica Bernard; Dirk Rades; Hendrik Lehnert; Kim Barbara Luley; Christoph Thorns

doi:10.3109/10428194.2015.1046863

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective

Niklas Gebauer^*, Harald Biersack, Ann Cathrin Czerwinska, Janina Schemme, Tim Tristan Hardel, Veronica Bernard, Dirk Rades, Hendrik Lehnert, Kim Barbara Luley, Christoph Thorns

^*Corresponding author for this work

9 Citations (Scopus)

Original language	English
Journal	Leukemia and Lymphoma
Volume	57
Issue number	1
Pages (from-to)	226-229
Number of pages	4
ISSN	1042-8194
DOIs	https://doi.org/10.3109/10428194.2015.1046863
Publication status	Published - 02.01.2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428194.2015.1046863

Cite this

Gebauer, N., Biersack, H., Czerwinska, A. C., Schemme, J., Hardel, T. T., Bernard, V., Rades, D., Lehnert, H., Luley, K. B., & Thorns, C. (2016). Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective. Leukemia and Lymphoma, 57(1), 226-229. https://doi.org/10.3109/10428194.2015.1046863

@article{6d487659d6a94cb29b7a2f3d07bd24dc,

title = "Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective",

author = "Niklas Gebauer and Harald Biersack and Czerwinska, \{Ann Cathrin\} and Janina Schemme and Hardel, \{Tim Tristan\} and Veronica Bernard and Dirk Rades and Hendrik Lehnert and Luley, \{Kim Barbara\} and Christoph Thorns",

year = "2016",

month = jan,

day = "2",

doi = "10.3109/10428194.2015.1046863",

language = "English",

volume = "57",

pages = "226--229",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Gebauer, N , Biersack, H, Czerwinska, AC, Schemme, J, Hardel, TT, Bernard, V, Rades, D, Lehnert, H, Luley, KB & Thorns, C 2016, 'Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective', Leukemia and Lymphoma, vol. 57, no. 1, pp. 226-229. https://doi.org/10.3109/10428194.2015.1046863

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective. / Gebauer, Niklas ; Biersack, Harald; Czerwinska, Ann Cathrin et al.
In: Leukemia and Lymphoma, Vol. 57, No. 1, 02.01.2016, p. 226-229.

Research output: Journal Articles › Letters › peer-review

TY - JOUR

T1 - Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective

AU - Gebauer, Niklas

AU - Biersack, Harald

AU - Czerwinska, Ann Cathrin

AU - Schemme, Janina

AU - Hardel, Tim Tristan

AU - Bernard, Veronica

AU - Rades, Dirk

AU - Lehnert, Hendrik

AU - Luley, Kim Barbara

AU - Thorns, Christoph

PY - 2016/1/2

Y1 - 2016/1/2

UR - https://www.scopus.com/pages/publications/84954244341

U2 - 10.3109/10428194.2015.1046863

DO - 10.3109/10428194.2015.1046863

M3 - Letters

C2 - 25947035

AN - SCOPUS:84954244341

SN - 1042-8194

VL - 57

SP - 226

EP - 229

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: A single center perspective

UN SDGs

Access to Document

Other files and links

Cite this